

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)



(10) International Publication Number
WO 2022/221697 A1

(51) International Patent Classification:

A61K 9/127 (2006.01) C12N 15/88 (2006.01)

A61K 47/28 (2006.01) C12N 15/90 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/025076

(22) International Filing Date:

15 April 2022 (15.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/176,227 17 April 2021 (17.04.2021) US

63/254,948 12 October 2021 (12.10.2021) US

63/274,153 01 November 2021 (01.11.2021) US

63/316,568 04 March 2022 (04.03.2022) US

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(71) Applicant: **INTELLIA THERAPEUTICS, INC.**
[US/US]; 40 Erie Street, Cambridge, MA 02139 (US).

(72) Inventors: **SWAMI, Archana**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **RAKSHE, Vishal**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **PRODEUS, Aaron**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **MAETANI, Micah**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **PARMAR, Rubina, Giare**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US).

(74) Agent: **HALSTEAD, David, P.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: LIPID NANOPARTICLE COMPOSITIONS

(57) Abstract: The disclosure provides lipid nanoparticle (LNP) compositions of ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.



WO 2022/221697 A1